Relationship between CYP2C19 loss-of-function polymorphism and platelet reactivities with clopidogrel treatment in Japanese patients undergoing coronary stent implantation

Circulation Journal

Volumn 77, Issue 6, 2013, Pages 1436-1444

  Nakata, Tomoyuki ^a   Miyahara, Masatoshi ^a   Nakatani, Kaname ^b   Wada, Hideo ^b   Tanigawa, Takashi ^c   Komada, Fumihiko ^d   Hoshino, Kozo ^e   Aoki, Toshikazu ^f   Nishimura, Yuki ^g   Tamaru, Satoshi ^g   Ito, Masaaki ^a   Nishikawa, Masakatsu ^g  

^a Department of Cardiology ^*  (Japan)

^b Molecular and Laboratory Medicine   (Japan)

^c Matsusaka Chuo General Hospital   (Japan)

^d Matsusaka Central Hospital   (Japan)

^e Nagai Hospital   (Japan)

^f Tohyama Hospital   (Japan)

^g MIE UNIVERSITY HOSPITAL   (Japan)

Author keywords

Clopidogrel; CYP2C19; Platelet reactivity; Stent; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYTOCHROME P450 2C19; HISTAMINE H2 RECEPTOR ANTAGONIST; PADGEM PROTEIN; PROTON PUMP INHIBITOR;

AGED; ARTICLE; CORONARY STENT; DISEASE ASSOCIATION; DRUG ELUTING STENT; ELISA KIT; FEMALE; FLOW CYTOMETRY; HUMAN; ISCHEMIC HEART DISEASE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PHOSPHORYLATION; PLATELET MICROPARTICLE; PLATELET REACTIVITY; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SHEAR STRESS; THROMBOCYTE COUNT;

ARYL HYDROCARBON HYDROXYLASES; ASIAN CONTINENTAL ANCESTRY GROUP; CELL ADHESION MOLECULES; CORONARY VESSELS; HUMANS; JAPAN; MICROFILAMENT PROTEINS; MYOCARDIAL ISCHEMIA; P-SELECTIN; PHOSPHOPROTEINS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; STENTS; TICLOPIDINE;

EID: 84878249363     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-1095     Document Type: Article

References (31)

1. Cross J. Antiplatelet therapy for improving post-PCI outcomes: Interpreting current treatment guidelines for optimal management of the post-ACS patient. Am J Manag Care 2009; 15(Suppl): S48-S53.
2. Frere C, Cuisset T, Quilici J, Camoin L, Carvajal J, Morange PE, et al. ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost 2007; 98: 838-843.
3. Sibbing D, Braun S, Morath T, Mehilli J, Vogt W, Schömig A, et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009; 53: 849- 856.
4. Price MJ, Endemann S, Gollapudi RR, Valencia R, Stinis CT, Levisay JP, et al. Prognostic signifcance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008; 29: 992-1000.
5. Angiolillo DJ, Suryadevara S, Capranzano P, Zenni MZ, Guzman LA, Bass TA. Antiplatelet drug response variability and the role of platelet function testing: A practical guide for interventional cardiologists. Catheter Cardiovasc Interv 2009; 73: 1-14.
6. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJT, Bal ET, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010; 303: 754-762.
7. Sobieraj-Teague M, Eikelboom JW. Point-of-care testing for assessment of adequacy of oral antiplatelet therapy in patients with cardiovascular disease. Future Cardiol 2010; 6: 289-299.
8. Nagy B Jr, Szuk T, Debreceni IB, Kappelmayer J. Platelet derived microparticle levels are significantly elevated in patients treated by elective stenting compared to subjects with diagnostic catheterization alone. Platelets 2011; 21: 147-151.
9. Patlig G, Chello M, Pasceri V, Colonna D, Colonna G, Pepe LL, et al. Pretreatment with different loading dose of clopidogrel influences P-selectin levels in patients undergoing percutaneous coronary intervention: Results from the ARMYDA-2 SELECT substudy. Cardio-vasc Med 2011; 12: 151-156.
10. Tanigawa T, Nishikawa M, Kitai T, Ueda Y, Okinaka T, Makino K, et al. Increased platelet aggregability in response to shear stress in acute myocardial infarction and its inhibition by combined therapy with aspirin and cilostazol after coronary intervention. Am J Cardiol 2000; 85: 1054-1059.
11. Motoda C, Ueda H, Hayashi Y, Toyofuku M, Okimoto T, Otsuka M, et al. Impact of platelet reactivity to adenosine diphosphate before implantation of drug-eluting stent on subsequent adverse cardiac events in patients with stable angina. Circ J 2012; 76: 641-649.
12. Momary KM, Dorsch MP. Factors associated with clopidogrel non-responsiveness. Future Cardiol 2010; 6: 195-210.
13. Geisler T, Schaeffeler E, Dippon J, Winter S, Buse V, Bischofs C, et al. CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharma-cogenomics 2008; 9: 1251-1259.
14. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-362.
15. Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Méneveau N, et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360: 363-375.
16. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical effcacy of clopidogrel therapy. JAMA 2009; 302: 849-857.
17. Hulot JS, Collet JP, Silvain J, Pena A, Bellemain-Appaix A, Barthélémy O, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: A systematic meta-anal-ysis. J Am Coll Cardiol 2010; 56: 134-143.
18. Sawada T, Shinke T, Shite J, Honjo T, Haraguchi Y, Nishio R, et al. Impact of cytochrome P450 2C19*2 polymorphism on intra-stent thrombus after drug-eluting stent implantation in Japanese patients receiving clopidogrel. Circ J 2011; 75: 99-105.
19. Nishio R, Shinke T, Otake H, Sawada T, Haraguchi Y, Shinohara M, et al. Effect of cytochrome P450 2C19 polyporphism on target lesion outcome after drug-eluting stent implantation in Japanese patients receiving clopidogrel. Circ J 2012; 76: 2348-2355.
20. Lee JM, Park S, Shin DJ, Choi D, Shim CY, Ko YG, et al. Relation of genetic polymorphisms in the cytochrome P450 gene with clopi-dogrel resistance after drug-eluting stent implantation in Koreans. Am J Cardiol 2009; 104: 46-51.
21. Goldstein JA, Ishizaki T, Chiba K, de Morais SM, Bell D, Krahn PM, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharma-cogenetics 1997; 7: 59-64.
22. Jinnai T, Horiuchi H, Makiyama T, Tazaki J, Tada T, Akao M, et al. Impact of CYP2C19 polymorphism on the antiplatelet effect of clop-idogrel in an actual clinical setting in Japan. Circ J 2009; 73: 1498-1503.
23. Yamamoto K, Hokimoto S, Chitose T, Morita K, Ono T, Kaikita K, et al. Impact of CYP2C19 polymorphism on residual platelet reactivity in patients with coronary heart disease during antiplatelet therapy. J Cardiol 2011; 57: 194-201.
24. Campo G, Parrinello G, Ferraresi P, Lunghi B, Tebaldi M, Miccoli M, et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J Am Coll Cardiol 2011; 57: 2474-2483.
25. Bouman HJ, Harmsze AM, van Werkum JW, Breet NJ, Bergmeijer TO, ten Cate H, et al. Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pre-treated patients undergoing coronary stenting. Heart 2011; 97: 1239-1244.
26. Bouman HJ, Parlak E, van Werkum JW, Breet NJ, ten Cate H, Hackeng CM, et al. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel. J Thromb Haemost 2010; 8: 482-488.
27. Sof F, Marcucci R, Gori AM, Giusti B, Abbate R, Gensini GF. Clopidogrel non-responsiveness and risk of cardiovascular morbidity: An updated meta-analysis. Thromb Haemost 2010; 103: 841-848.
28. Bonello L, Camoin-Jau L, Arques S, Boyer C, Panagides D, Wittenberg O, et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter randomized prospective study. J Am Coll Cardiol 2008; 51: 1404-1411.
29. Paniccia R, Antonucci E, Gori AM, Marcucci R, Giglioli C, Antoniucci D, et al. Different methodologies for evaluating the effect of clopi-dogrel on platelet function in high-risk coronary artery disease patients. J Thromb Haemost 2007; 5: 1839-1847.
30. Gremmel T, Steiner S, Seidinger D, Koppensteiner R, Panzer S, Kopp CW. Comparison of methods to evaluate clopidogrel-mediated platelet inhibition after percutaneous intervention with stent implantation. Thromb Haemost 2009; 101: 333-339.
31. Kimura T, Morimoto T, Nakagawa Y, Tamura T, Kadota K, Yasumoto H, et al; j-Cypher Registry Investigators. Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation 2009; 119: 987-995.